a randomized, comparative trial of zdv versus zdv plus ddi versus zdv plus ddc in persons with cd4 cell counts of less than 200/mm3.

NLM AIDSLINE A randomized, comparative trial of ZDV versus ZDV plus ddI versus ZDV plus ddC in persons with CD4 cell counts of less than 200/mm3. Saravolatz L; Collins G; Hodges J; Winslow D; NIAID, Bethesda, Maryland.
November 30, 1996

3rd Conf Retro and Opportun Infect. 1996 Jan 28-Feb 1;:161. Unique Despite widespread use of combination nucleoside therapy in patients with AIDS (1993 CDC definition), a clinical benefit has yet to be demonstrated in terms of delaying opportunistic diseases or death. CPCRA 007 was designed to compare the efficacy of ZDV alone, ZDV given with ddI, and ZDV given with ddC in delaying disease progression or death in patients with AIDS. 1113 patients (254 antiretroviral naive, 859 antiretroviral experienced) were randomized openly to ZDV (600mg/d) and ddI or ZDV and ddC and then randomized in a double blind fashion, in a 2:1 ratio, either to active ddI (400 mg/d) or its placebo or to active ddC (2.25 mg/d) or its placebo. Baseline characteristics were well balanced among treatment arms and overall the participants were: 92% male, 33% African American, 10% Hispanic, 68% homosexual, and 23% intravenous drug users. The mean CD4+ count was 119 cells/mm3 and the median prior ZDV use was 6 months. Prior AIDS defining opportunistic infections and prior Pneumocystis carinii pneumonia (PCP) were present on enrollment in 32% and 23% of patients respectively. PCP prophylaxis was required for all participants and did not differ significantly in terms of the agent selected. All patients were followed for at least 17 months and the median followup was 35 months. 4% of enrollees were lost to followup. The mean time on blinded study drugs were 13, 14 and 14 in the ZDV + ddI, ZDV + ddC, and ZDV only groups, respectively. The study closed to followup on November 30, 1995 and is currently under analysis. Difference in treatment arms have been analyzed and detailed results will be reported. The study has important implications for patient management. Acquired Immunodeficiency Syndrome/COMPLICATIONS/DRUG THERAPY/ PHYSIOPATHOLOGY Antiviral Agents/THERAPEUTIC USE CD4 Lymphocyte Count Comparative Study Didanosine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Drug Therapy, Combination Female Human Male Pneumonia, Pneumocystis carinii/PREVENTION & CONTROL Zalcitabine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Zidovudine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE ABSTRACT

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV No time to lose in the search for an HIV vaccine India Widens Price Control Over Medicines Health group didn't disclose HIV tests, apologizes As Hepatitis C Spreads, Scotland Steps In Russia has 'no anti-AIDS strategy': official Uganda: Over 600 Circumcised in Masaka 1 new hepatitis case in Okla. public health scare NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs PENNSYLVANIA: Scientists Weaken HIV Infection in Immune Cells Using Synthetic Agents Experimental Gilead drug effective in early-stage leukemia trial MARYLAND: People More Likely to Keep HIV Clinic Appointments if They Believe Their Care Providers Know Them as a Person Antiretroviral regimen associated with less virological failure among HIV-infected children Jury to be seated, Vegas hep C trial due to start AFRICA: Less-Used HIV Treatment for African Children More Effective KYRGYZSTAN: At Least 3,377 Drug-Resistant TB Cases Registered in Kyrgyzstan Vieillir avec le VIH, un nouveau défi pour 10.000 personnes de plus de 60 ans Less-used drug better treats HIV in kids: study Less-Used HIV Treatment for African Children More Effective
Information in this article was accurate in November 30, 1996. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.